ProCE Banner Activity

Multiple Myeloma: Diagnosis and Treatment for 2022

PDF
Download this summary resource for a quick guide to 2022 recommendations from experts in myeloma care.

Released: January 31, 2022

Expiration: January 30, 2023

No longer available for credit.

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Vincent A. Miller

Vincent A. Miller, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Jesus San-Miguel

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner

Program Director Disclosure

Program Director

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees from non-CME/CE services from Amgen.

Faculty Disclosure

Primary Author

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received funds for research support from Amgen, Johnson & Johnson / Janssen, Sanofi, and Seattle Genetics, and has received consulting funds from GlaxoSmithKline and Oncopeptides.

Vincent A. Miller, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, New York

S. Vincent Rajkumar, MD has no relevant conflicts of interest to disclose.

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, and Sanofi.

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda.